Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Glycerol esterified with stearic acid, used as an emulsifier and as a glycerol carrier for pre-exercise hyperhydration; studied for its effect on fluid retention, thermoregulation and endurance performance.
17 of 31 results reported a benefit, from 7 published studies.
7 studies, including a review of trials
Side effects: measured in 1 result. No result reported more side effects than the comparison group.
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultSustained physical performance — cardiovascular capacity, stamina, and oxygen utilisation during prolonged exercise.
Also known as: Glyceryl monostearate, Glycerol 1-stearate, glycerol hyperhydration
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for Glycerol Monostearate in endurance.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Be the first to share what you noticed with Glycerol Monostearate for endurance. Why counts start empty.
Outcomes reported as percentage changes for Glycerol Monostearate. Other units sit in the table above.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 38198662 2024 | Meta-analysis | - | - | Body temperature post-performance task | reported qualitatively (p = 0.349) | No benefit |
| PMID 38198662 2024 | Meta-analysis | - | - | Body temperature post-performance task | 0.80 (p = 0.046) | Benefit |
| PMID 38198662 2024 | Meta-analysis | - | - | Body temperature post-SS | reported qualitatively (p = 0.132) | No benefit |
| PMID 38198662 2024 | Meta-analysis | - | - | Heart rate during performance task | reported qualitatively (p = 0.072) | No benefit |
| PMID 38198662 2024 | Meta-analysis | - | - | Heart rate following steady state (SS) exercise | reported qualitatively (p = 0.069) | No benefit |
| PMID 38198662 2024 | Meta-analysis | - | - | Time trial (TT) | 0.25 (95% CI: 0.002-0.51; p = 0.049) | Benefit |
| PMID 38198662 2024 | Meta-analysis | - | - | Time-to-exhaustion (TTE) | 0.31 (95% CI: 0.13-0.50; p = 0.001) | Benefit |
| PMID 38198662 2024 | Meta-analysis | - | - | Total work (TW) tasks | reported qualitatively (p = 0.120) | No benefit |
| PMID 17962713 2007 | Meta-analysis | - | - | Endurance performance (EP) | 2.62% +/- 1.60% % (P = 0.047; PES: 0.35 +/- 0.13, P = 0.014, N = 4) | Benefit |
| PMID 40139199 2025 | Randomised trial | 13 | 180-minute | Exercise performance (half-marathon time-trial) | reported qualitatively (P > .05) | No benefit |
| PMID 40139199 2025 | Randomised trial | 13 | 180-minute | Fluid retention | reported qualitatively (95% CI 987-1391, P < .001) | Benefit |
| PMID 40139199 2025 | Randomised trial | 13 | 180-minute | Gastrointestinal symptoms | reported qualitatively (P > .05) | No benefit |
| PMID 40139199 2025 | Randomised trial | 13 | 180-minute | Gastrointestinal temperature | reported qualitatively (P > .05) | No benefit |
| PMID 40139199 2025 | Randomised trial | 13 | 180-minute | Heart rate | reported qualitatively (P > .05) | No benefit |
| PMID 40139199 2025 | Randomised trial | 13 | 180-minute | Plasma volume | 9.0% (95% CI 3.6-14.4, P = .001) | Benefit |
| PMID 18838842 2008 | Randomised trial | 6 | 2 h | Body mass loss at end of exercise | 1.7+/-0.3% % (p<0.05) | Benefit |
| PMID 18838842 2008 | Randomised trial | 6 | 2 h | Fluid ingestion during exercise replaced % of sweat losses | 31.0+/-2.9% % (p>0.05) | No benefit |
| PMID 16604127 2006 | Randomised trial | 6 | 2 h | Urine production | 246 mL | Benefit |
| PMID 11591882 2001 | Randomised trial | 6 | - | Circulating catecholamines | reported qualitatively | No benefit |
| PMID 11591882 2001 | Randomised trial | 6 | - | Forearm blood flow | reported qualitatively (p < .05) | Benefit |
| PMID 11591882 2001 | Randomised trial | 6 | - | Heart rate | reported qualitatively | Benefit |
| PMID 11591882 2001 | Randomised trial | 6 | - | Muscle metabolism markers (glycogenolysis, lactate, adenine nucleotide, phosphocreatine, inosine 5'-monophosphate) | reported qualitatively | No benefit |
| PMID 11591882 2001 | Randomised trial | 6 | - | Pre-exercise urine volume | reported qualitatively (p < .05) | Benefit |
| PMID 11591882 2001 | Randomised trial | 6 | - | Rectal temperature | 38.7 +/- 0.1 vs. 39.1 +/- 0.1 degrees C (p < .05) | Benefit |
| PMID 11591882 2001 | Randomised trial | 6 | - | Skin and muscle temperatures | reported qualitatively | No benefit |
| PMID 11591882 2001 | Randomised trial | 6 | - | Work performed during PC | 252 +/- 10 vs. 240 +/- 9 kJ (p < .05) | Benefit |
| PMID 8775573 1996 | Randomised trial | 11 | Study I | endurance time (ET) | 93.8 +/- 14 min min (p = 0.049) | Benefit |
| PMID 8775573 1996 | Randomised trial | 7 | Study II | endurance time (ET) | 123.4 +/- 17 min min (p = 0.03) | Benefit |
| PMID 8775573 1996 | Randomised trial | 11 | Study I | heart rate (HR) | 2.8 +/- 0.4 beats/min beats/min (p = 0.05) | Benefit |
| PMID 8775573 1996 | Randomised trial | 7 | Study II | heart rate (HR) | 4.4 +/- 1.1 beats/min beats/min (p = 0.01) | Benefit |
| PMID 8775573 1996 | Randomised trial | 11 | Study I | rectal temperature (Tc) | reported qualitatively | No benefit |
| PMID 8775573 1996 | Randomised trial | 7 | Study II | rectal temperature (Tc) | reported qualitatively | No benefit |